Retrophin, Inc. (RTRX) Shares Bought by Teachers Advisors LLC
Teachers Advisors LLC grew its stake in Retrophin, Inc. (NASDAQ:RTRX) by 0.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 370,249 shares of the biopharmaceutical company’s stock after acquiring an additional 2,975 shares during the period. Teachers Advisors LLC owned 0.97% of Retrophin worth $7,179,000 at the end of the most recent reporting period.
A number of other hedge funds also recently modified their holdings of RTRX. Nationwide Fund Advisors grew its stake in Retrophin by 129.9% in the 1st quarter. Nationwide Fund Advisors now owns 51,841 shares of the biopharmaceutical company’s stock worth $957,000 after acquiring an additional 29,290 shares in the last quarter. Wells Fargo & Company MN grew its stake in Retrophin by 12.8% in the 1st quarter. Wells Fargo & Company MN now owns 50,785 shares of the biopharmaceutical company’s stock worth $938,000 after acquiring an additional 5,763 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Retrophin by 14,062.4% in the 1st quarter. JPMorgan Chase & Co. now owns 131,852 shares of the biopharmaceutical company’s stock worth $2,434,000 after acquiring an additional 130,921 shares in the last quarter. American International Group Inc. grew its stake in Retrophin by 7.1% in the 1st quarter. American International Group Inc. now owns 22,300 shares of the biopharmaceutical company’s stock worth $412,000 after acquiring an additional 1,475 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in Retrophin in the 1st quarter worth about $219,000.
In other Retrophin news, COO Neil F. Mcfarlane sold 1,378 shares of Retrophin stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $22.50, for a total transaction of $31,005.00. Following the completion of the sale, the chief operating officer now directly owns 13,622 shares in the company, valued at $306,495. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.41% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Retrophin, Inc. (RTRX) Shares Bought by Teachers Advisors LLC” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/07/retrophin-inc-rtrx-shares-bought-by-teachers-advisors-llc.html.
Retrophin, Inc. (NASDAQ:RTRX) opened at 24.72 on Friday. The company’s market capitalization is $948.88 million. Retrophin, Inc. has a 52 week low of $15.55 and a 52 week high of $25.44. The firm has a 50-day moving average of $23.99 and a 200-day moving average of $20.09.
Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The company had revenue of $38.80 million for the quarter, compared to analyst estimates of $37.36 million. During the same quarter in the prior year, the business earned $0.07 earnings per share. Retrophin’s revenue was up 16.5% on a year-over-year basis. Analysts anticipate that Retrophin, Inc. will post ($1.13) EPS for the current fiscal year.
A number of equities analysts have commented on RTRX shares. BidaskClub upgraded shares of Retrophin from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th. ValuEngine upgraded shares of Retrophin from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Retrophin has a consensus rating of “Buy” and an average price target of $36.50.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin, Inc. (NASDAQ:RTRX).
Receive News & Stock Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related stocks with our FREE daily email newsletter.